Back to Journals » Infection and Drug Resistance » Volume 11

Efficiency of gold nanoparticles coated with the antimicrobial peptide indolicidin against biofilm formation and development of Candida spp. clinical isolates

Authors de Alteriis E, Maselli V, Falanga A, Galdiero S, Di Lella FM, Gesuele R, Guida M, Galdiero E

Received 1 February 2018

Accepted for publication 29 March 2018

Published 3 July 2018 Volume 2018:11 Pages 915—925


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Dr Joachim Wink

Elisabetta de Alteriis,1 Valeria Maselli,1 Annarita Falanga,2 Stefania Galdiero,2 Federica Maria Di Lella,3 Renato Gesuele,1 Marco Guida,1 Emilia Galdiero1

1Department of Biology, University of Naples “Federico II”, Naples, Italy; 2Department of Pharmacy, University of Naples “Federico II”, Naples, Italy; 3Section of Microbiology and Virology, University Hospital “Luigi Vanvitelli” of Naples, Naples, Italy

Background: This article examines the use of a novel nano-system, gold nanoparticles coated with indolicidin (AuNPs–indolicidin), against pathogenic Candida albicans biofilms. Candida species cause frequent infections owing to their ability to form biofilms, primarily on implant devices.
Materials and methods: We used an integrated approach, evaluating the effect of AuNPs-indolicidin on prevention and eradication of Candida biofilms formed in multi-well polystyrene plates, with relative gene expression assays. Four biofilm-associated genes (FG1, HWP1, ALS1 and ALS3, and CDR1 and CDR2) involved in efflux pump were analyzed using reverse transcription polymerase chain reaction.
Treatment with the nano-complex significantly inhibits the capacity of C. albicans to form biofilms and impairs preformed mature biofilms. Treatment with AuNPs–indolicidin results in an increase in the kinetics of Rhodamine 6G efflux and a reduction in the expression of biofilm-related genes.
Conclusion: These data provide a chance to develop novel therapies against nosocomially acquired refractory C. albicans biofilms.

Keywords: antimicrobial activity, anti-biofilm activity, fungal biofilm, drug resistance, fungal infections

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]